DOHH-2

DOHH-2 is a human diffuse large B-cell lymphoma (DLBCL) cell line that is used to model various aspects of B-cell malignancies, including drug resistance and treatment efficacy. This cell line is particularly valuable for assessing the impact of targeted therapies and combination regimens on tumor growth. Studies have shown that DOHH-2 cells respond to the Bcl-2 inhibitor ABT-263 (navitoclax), which has been tested in combination with various chemotherapeutic agents to enhance treatment efficacy. For example, the addition of ABT-263 to etoposide and vincristine has been found to yield additive effects on cell survival and apoptosis, demonstrating its potential to improve outcomes in combination treatments for DLBCL. In vivo models involving DOHH-2 also show that combining ABT-263 with regimens like CHOP can significantly increase tumor response rates and delay tumor growth, underscoring its utility in preclinical drug testing.

DOHH-2 has also been studied for its response to various targeted therapies beyond traditional chemotherapy. In particular, the triple combination of the CD20 antibody obinutuzumab with the Bcl-2 inhibitor venetoclax and the MDM2 inhibitor idasanutlin demonstrated superior efficacy in reducing tumor size and achieving complete remission in preclinical models. This approach highlights DOHH-2’s role in advancing novel therapeutic strategies aimed at achieving better long-term control of DLBCL.

37°C, 5% CO₂, humidified atmosphere.

1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

6. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium.

7. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth.

8. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.

Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods.

To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections.

For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.

At Cytion, we stand behind the quality and viability of our products. We guarantee that our cells will be viable at the start of culture for 60 days after shipment from our facilities. We assure that all materials conform to the specifications described in the Certificate of Analysis and/or Product Sheet.

For full details, please refer to our Warranty Statement.